NMD Pharma is a clinical-stage biotech spun off from Aarhus University that has developed a muscle electrophysiology platform and small-molecule modulators targeting the skeletal muscle chloride channel ClC-1. Led by CEO Thomas Holm Pedersen, the company focuses on discovering proprietary modulators of neuromuscular function using enabling technologies, in vivo pharmacology models, and muscle physiology know-how. Its lead program is NMD670, a ClC-1 inhibitor advancing into clinical trials. The company raised €75M in a Series B to fund near-term clinical development. Proceeds will be used to complete three Phase 2 studies evaluating NMD670 in AChR- and MuSK-antibody positive myasthenia gravis, spinal muscular atrophy, and Charcot–Marie–Tooth disease. NMD Pharma also plans to expand its pipeline of ClC-1 inhibitor molecules, pursue additional undisclosed neuromuscular targets, and grow its clinical and commercial operations in Denmark and the US. NMD Pharma is a Danish clinical-stage biotech focused on developing breakthrough therapies for patients with severe neuromuscular disorders. Its lead candidate, NMD670, is being developed to treat symptoms of Myasthenia Gravis, and the company maintains a CLC-1 inhibitor portfolio. NMD Pharma has built a platform and a high level of expertise specifically dedicated to the neuromuscular field. The company raised a €35 million financing led by Jeito Capital. The financing is intended to expand clinical programs into several neuromuscular diseases, including spinal muscular atrophy, grow the pipeline, and support expansion to new targets. Jeito Capital will also support market entry strategy and has joined the board to assist the company as it advances development toward patients.

Total raised

$121M

Funding rounds

2

Latest round

Series B

Latest activity

Nov 2023